CIRCADIN

Serial Number 75546291
606

Registration Progress

Application Filed
Sep 1, 1998
Under Examination
Oct 19, 1999
Approved for Publication
Jun 25, 1999
Published for Opposition
Jul 27, 1999
Registered

Trademark Image

CIRCADIN

Basic Information

Serial Number
75546291
Filing Date
September 1, 1998
Published for Opposition
July 27, 1999
Abandonment Date
October 20, 2002
Drawing Code
1000

Status Summary

Current Status
Inactive
Status Code
606
Status Date
Oct 20, 2002
Classes
005

Rights Holder

Neurim Pharmaceuticals (1991) Ltd.

03
Address
8 Hanechoshet Street
Tel Aviv 69710
IL

Ownership History

Neurim Pharmaceuticals (1991) Ltd.

Original Applicant
03
Tel Aviv 69710 IL

Neurim Pharmaceuticals (1991) Ltd.

Owner at Publication
03
Tel Aviv 69710 IL

Legal Representation

Attorney
Lawrence E. Abelman

USPTO Deadlines

All Deadlines Cleared

All 2 deadline(s) have been cleared by subsequent events. No active deadlines at this time.

Application History

17 events
Date Code Type Description Documents
May 24, 2003 ABN6 S ABANDONMENT - NO USE STATEMENT FILED Loading...
Apr 20, 2002 EX5G S SOU EXTENSION 5 GRANTED Loading...
Apr 3, 2002 EXT5 S SOU EXTENSION 5 FILED Loading...
Oct 16, 2001 EXT4 S SOU EXTENSION 4 FILED Loading...
Oct 16, 2001 EX4G S SOU EXTENSION 4 GRANTED Loading...
Apr 24, 2001 EX3G S SOU EXTENSION 3 GRANTED Loading...
Apr 3, 2001 EXT3 S SOU EXTENSION 3 FILED Loading...
Dec 12, 2000 EX2G S SOU EXTENSION 2 GRANTED Loading...
Sep 26, 2000 EXT2 S SOU EXTENSION 2 FILED Loading...
Jun 29, 2000 EX1G S SOU EXTENSION 1 GRANTED Loading...
Mar 16, 2000 EXT1 S SOU EXTENSION 1 FILED Loading...
Oct 19, 1999 NOAM O NOA MAILED - SOU REQUIRED FROM APPLICANT Loading...
Jul 27, 1999 PUBO A PUBLISHED FOR OPPOSITION Loading...
Jun 25, 1999 NPUB O NOTICE OF PUBLICATION Loading...
Apr 27, 1999 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Apr 19, 1999 CNEA F EXAMINER'S AMENDMENT MAILED Loading...
Apr 13, 1999 DOCK D ASSIGNED TO EXAMINER Loading...

Detailed Classifications

Class 005
pharmaceutical preparations for use in the treatment of melatonin deficiency, in a controlled-release form
First Use Anywhere: 0
First Use in Commerce: 0

Classification

International Classes
005